샘플 요청 목록

 카트 문의
시장보고서
상품코드
1788323

세계의 RNA 타겟 저분자 Drug Discovery 시장

RNA Targeting Small Molecule Drug Discovery
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 173 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 RNA 타겟 저분자 Drug Discovery 시장은 2030년까지 53억 달러에 도달

2024년에 18억 달러로 추정되는 세계의 RNA 타겟 저분자 Drug Discovery 시장은 2024-2030년의 분석 기간에 CAGR 19.9%로 성장하며, 2030년에는 53억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 암은 CAGR 18.1%를 기록하며, 분석 기간 종료시에는 20억 달러에 달할 것으로 예측됩니다. 감염증 분야의 성장률은 분석 기간의 CAGR로 20.7%로 추정됩니다.

미국 시장은 4억 7,110만 달러로 추정, 중국은 CAGR 19.0%로 성장 예측

미국의 RNA 타겟 저분자 Drug Discovery 시장은 2024년에 4억 7,110만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 8억 2,310만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 19.0%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 각각 분석 기간 중 17.9%와 17.3%의 CAGR로 성장할 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 13.9%로 성장할 것으로 예측됩니다.

세계의 RNA 타겟 저분자 Drug Discovery 시장 - 주요 동향과 촉진요인 정리

RNA 타겟팅이 신약개발의 혁명적 접근법으로 부상하고 있는 이유는 무엇인가?

신약개발 분야에서는 기존의 단백질 기반 치료제에서 벗어나 획기적인 접근 방식인 RNA 표적 소분자에 대한 관심이 높아지면서 패러다임의 전환이 일어나고 있습니다. RNA는 유전자 발현과 조절에 중요한 역할을 하며, 암, 신경퇴행성 질환, 바이러스 감염 등 다양한 질병을 치료할 수 있는 매력적인 표적이 되고 있습니다. 구조생물학과 하이스루풋 스크리닝 기술의 발전으로 RNA 구조에 선택적으로 결합할 수 있는 저분자를 식별할 수 있게 되어 새로운 치료의 길을 열었습니다. 2차 구조를 안정화하거나 RNA와 단백질의 상호작용을 억제함으로써 RNA의 기능을 조절하는 저분자 화합물의 능력은 지금까지 치료할 수 없었던 표적을 치료할 수 있는 가능성을 열어주고 있습니다. 또한 계산 모델링과 AI를 활용한 약물 스크리닝의 개발로 강력한 RNA 표적 화합물의 발견이 가속화되고 있습니다. RNA 전문 라이브러리와 단편 기반 신약개발 접근법의 통합은 이 새로운 영역의 정확성과 효율성을 더욱 향상시켜 RNA 표적 치료제를 현대 의학의 혁신적 힘으로 자리매김하고 있습니다.

최근 RNA 생물학 분야의 획기적인 발전이 시장 확대를 어떻게 촉진하고 있는가?

최근 RNA 생물학의 발전은 RNA 표적 저분자 의약품의 개발을 크게 촉진하여 질병 경로에 대한 보다 정확한 개입을 가능하게 하고 있습니다. 리보스위치, 긴 비암호화 RNA(lncRNA), 마이크로 RNA 등 기능성 RNA 구조의 발견으로 치료 표적의 범위가 넓어지고 있습니다. 연구진은 현재 극저온 전자현미경(cryo-Em) 및 NMR 분광법과 같은 RNA 구조 매핑 기술을 활용하여 매우 특이적인 치료 가능한 RNA 모티브를 식별하고 있습니다. 또한 mRNA 백신과 안티센스 올리고뉴클레오티드와 같은 RNA 기반 치료제의 성공은 치료 표적으로서의 RNA의 큰 잠재력을 강조하고 있습니다. 기업은 차세대 RNA 타겟 라이브러리에 대한 투자를 늘려 저분자 후보 화합물을 보다 효과적으로 스크리닝하고 최적화할 수 있도록 하고 있습니다. 또한 RIBOTAC(리보뉴클레아제 표적 키메라)과 같은 RNA 분해 기술의 등장은 질병 관련 RNA 서열을 선택적으로 분해하는 새로운 전략을 제공합니다. 이러한 혁신은 RNA에 초점을 맞춘 신약 개발의 확장을 가속화하고, 막대한 투자를 유치하며, 바이오테크 기업과 제약 대기업의 전략적 제휴를 촉진하고 있습니다.

RNA 표적치료제에 대한 제약사 및 생명공학 기업의 관심이 높아지는 이유는 무엇인가?

제약회사와 생명공학 기업이 RNA 표적 저분자 화합물에 대한 관심을 높이는 배경에는 미충족 의료 수요에 대응하는 혁신적인 치료제에 대한 긴급한 요구가 있습니다. 단백질을 표적으로 하는 기존의 의약품 개발 접근법은 특히 복잡한 유전적 배경을 가진 질환에서는 한계가 있었습니다. RNA 표적 분자는 전사 수준에 개입하여 유해한 단백질이 합성되기 전에 질병의 진행을 막을 수 있는 대체 전략을 제공할 수 있습니다. 또한 RNA 고유의 구조적 가소성으로 인해 기존 단백질 억제제에 비해 더 다양한 타겟팅 기회를 제공합니다. 규제 당국이 새로운 RNA 표적 치료제의 조기 승인을 허용함에 따라 주요 제약사들은 RNA에 초점을 맞춘 파이프라인을 적극적으로 확장하고 있습니다. 전략적 제휴, 합병, 인수합병이 증가하고 있으며, 각 기업은 자체 RNA 표적 플랫폼에 많은 투자를 하고 있습니다. 저분자는 큰 RNA 기반 약물보다 세포에 더 효율적으로 침투할 수 있으므로 이 접근법의 상업적 매력은 더욱 커지고 있습니다. RNA 연구에 대한 자금이 지속적으로 증가하고 있는 가운데, 제약업계에서는 희귀 유전질환, 종양학, 감염성 질환을 해결하기 위한 RNA 표적화 프로그램이 급증하고 있습니다.

시장을 발전시키는 주요 성장 촉진요인은 무엇인가?

RNA 표적 저분자 신약 개발 시장의 성장은 RNA 구조 분석의 기술적 진보, 복잡한 질병의 유병률 증가, 혁신적인 치료제에 대한 수요 증가 등 여러 요인에 의해 주도되고 있습니다. 하이스루풋 스크리닝 기술의 확대와 AI를 활용한 신약개발 플랫폼이 결합하여 RNA 결합 분자의 식별이 크게 가속화되고 있습니다. 또한 mRNA 백신과 같은 RNA 기반 치료법의 성공은 RNA를 표적으로 하는 접근법에 대한 투자자들의 신뢰를 높이고 있습니다. RNA가 질병 진행에 있으며, 중요한 조절 요소로 인식되면서, 비암호화 RNA와 구조화된 RNA 요소를 표적으로 하는 새로운 치료 전략 개발에 박차를 가하고 있습니다. 제약업계의 맞춤형 의료 추진과 RNA 치료제에 초점을 맞춘 바이오테크 스타트업의 급격한 증가가 맞물려 시장 성장을 더욱 가속화하고 있습니다. RNA 표적 전략이 계속 진화하는 가운데, RNA에 초점을 맞춘 의약품 개발의 전략적 제휴, 규제 당국의 지원, 획기적인 기술 혁신에 힘입어 이 시장은 채택이 증가할 것으로 예측됩니다.

부문

적응증(암, 감염증, 대사성 질환, 신경질환, 기타); 최종사용자(제약·바이오파마 기업, 학술·연구기관, 기타)

조사 대상 기업의 예

  • Accent Therapeutics Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Anima Biotech Inc.
  • Arbutus Biopharma Corporation
  • Arrakis Therapeutics
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Dicerna Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Epics Therapeutics
  • Evotec SE
  • Expansion Therapeutics
  • F. Hoffmann-La Roche Ltd
  • H3 Biomedicine Inc.
  • Ionis Pharmaceuticals Inc.
  • Merck & Co., Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSA 25.08.18

Global RNA Targeting Small Molecule Drug Discovery Market to Reach US$5.3 Billion by 2030

The global market for RNA Targeting Small Molecule Drug Discovery estimated at US$1.8 Billion in the year 2024, is expected to reach US$5.3 Billion by 2030, growing at a CAGR of 19.9% over the analysis period 2024-2030. Cancer, one of the segments analyzed in the report, is expected to record a 18.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Infectious Diseases segment is estimated at 20.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$471.1 Million While China is Forecast to Grow at 19.0% CAGR

The RNA Targeting Small Molecule Drug Discovery market in the U.S. is estimated at US$471.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$823.1 Million by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.9% and 17.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global RNA Targeting Small Molecule Drug Discovery Market - Key Trends & Drivers Summarized

Why Is RNA Targeting Emerging As A Revolutionary Approach In Drug Discovery?

The field of drug discovery has witnessed a paradigm shift with the growing focus on RNA-targeting small molecules, a breakthrough approach that extends beyond traditional protein-based therapeutics. RNA plays a critical role in gene expression and regulation, making it an attractive target for treating a wide array of diseases, including cancer, neurodegenerative disorders, and viral infections. Advances in structural biology and high-throughput screening techniques have enabled the identification of small molecules that can selectively bind to RNA structures, offering novel therapeutic avenues. The ability of small molecules to modulate RNA function, either by stabilizing secondary structures or interfering with RNA-protein interactions, has opened up possibilities for treating previously undruggable targets. Additionally, the development of computational modeling and AI-driven drug screening is accelerating the discovery of potent RNA-targeting compounds. The integration of RNA-focused libraries and fragment-based drug discovery approaches is further enhancing the precision and efficiency of this emerging domain, positioning RNA-targeting therapeutics as a transformative force in modern medicine.

How Are Recent Breakthroughs In RNA Biology Driving Market Expansion?

Recent advances in RNA biology have significantly bolstered the development of RNA-targeting small molecule drugs, enabling more precise intervention in disease pathways. The discovery of functional RNA structures, such as riboswitches, long non-coding RNAs (lncRNAs), and microRNAs, has expanded the scope of therapeutic targets. Researchers are now leveraging RNA structural mapping techniques, including cryo-electron microscopy (cryo-EM) and NMR spectroscopy, to identify highly specific druggable RNA motifs. Additionally, the success of RNA-based therapeutics, such as mRNA vaccines and antisense oligonucleotides, has underscored the immense potential of RNA as a therapeutic target. Companies are increasingly investing in next-generation RNA-targeting libraries, enabling more effective screening and optimization of small-molecule candidates. Furthermore, the emergence of RNA degrader technologies, such as RIBOTACs (ribonuclease-targeting chimeras), is providing a novel strategy for selectively degrading disease-associated RNA sequences. These breakthroughs are accelerating the expansion of RNA-focused drug discovery, attracting significant investment and fostering strategic collaborations between biotech firms and pharmaceutical giants.

What Is Fueling The Interest Of Pharma & Biotech Companies In RNA-Targeted Therapies?

The growing interest of pharmaceutical and biotech companies in RNA-targeting small molecules is driven by the urgent need for innovative therapeutics that address unmet medical needs. Traditional drug development approaches targeting proteins have reached limitations, particularly in diseases with complex genetic underpinnings. RNA-targeting molecules offer an alternative strategy by intervening at the transcriptional level, potentially preventing disease progression before harmful proteins are even synthesized. Moreover, RNA’s inherent structural plasticity allows for more diverse targeting opportunities compared to conventional protein inhibitors. With regulatory bodies granting accelerated approvals for novel RNA-targeting therapeutics, major pharma players are actively expanding their RNA-focused pipelines. Strategic collaborations, mergers, and acquisitions are on the rise, with companies investing heavily in proprietary RNA-targeting platforms. The ability of small molecules to penetrate cells more efficiently than larger RNA-based drugs is further driving the commercial appeal of this approach. As funding for RNA research continues to grow, the pharmaceutical sector is witnessing a surge in RNA-targeting programs aimed at addressing rare genetic disorders, oncology, and infectious diseases.

What Are The Key Growth Drivers Propelling The Market Forward?

The growth in the RNA-targeting small molecule drug discovery market is driven by several factors, including technological advancements in RNA structural analysis, the rising prevalence of complex diseases, and the increasing demand for innovative therapeutics. The expansion of high-throughput screening techniques, coupled with AI-powered drug discovery platforms, is significantly accelerating the identification of RNA-binding molecules. Additionally, the success of RNA-based therapies, such as mRNA vaccines, has strengthened investor confidence in RNA-targeted approaches. The growing recognition of RNA as a critical regulatory element in disease progression is fueling the development of new therapeutic strategies targeting non-coding RNAs and structured RNA elements. The pharmaceutical industry's push towards personalized medicine, coupled with a surge in biotech startups focused on RNA therapeutics, is further amplifying market growth. As RNA-targeting strategies continue to evolve, the market is expected to witness increased adoption, backed by strategic collaborations, regulatory support, and breakthrough innovations in RNA-focused drug development.

SCOPE OF STUDY:

The report analyzes the RNA Targeting Small Molecule Drug Discovery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others); End-Use (Pharma & Biopharma Companies, Academic & Research Institutes, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Accent Therapeutics Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Anima Biotech Inc.
  • Arbutus Biopharma Corporation
  • Arrakis Therapeutics
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Dicerna Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Epics Therapeutics
  • Evotec SE
  • Expansion Therapeutics
  • F. Hoffmann-La Roche Ltd
  • H3 Biomedicine Inc.
  • Ionis Pharmaceuticals Inc.
  • Merck & Co., Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • RNA Targeting Small Molecule Drug Discovery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Understanding of RNA Biology Drives Expansion of RNA Targeting Small Molecule Drug Discovery
    • Rising Prevalence of Genetic Disorders and Cancer Expands Market Opportunities for RNA-Based Therapeutic Solutions
    • Technological Advancements in RNA Targeting and Modulation Tools Propel Growth in Small Molecule Drug Discovery
    • Surge in Investment in Precision Medicine Strengthens Business Case for RNA Targeting Small Molecule Drugs
    • Increasing Demand for Targeted Therapies Drives Market Adoption of RNA Modulators in Drug Development
    • Expanding Applications of RNA Targeting in Immuno-Oncology Create New Frontiers for Drug Discovery
    • Integration of AI and Machine Learning in Drug Discovery Accelerates the Identification of RNA Targets
    • Growth of Personalized Medicine Platforms Expands Addressable Market for RNA Targeting Drug Development
    • Rising Focus on Rare Diseases and Undruggable Targets Creates Opportunities for RNA Targeting Small Molecules
    • Increasing Role of RNA in Disease Mechanisms Strengthens Market Adoption of RNA Targeting Therapeutics
    • Regulatory Advancements and Incentives for Rare and Orphan Drug Development Propel RNA Targeting Drug Discovery
    • Surge in Academic and Industry Collaborations Drives Innovation in RNA Targeting Small Molecule Research
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World RNA Targeting Small Molecule Drug Discovery Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for RNA Targeting Small Molecule Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Metabolic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Metabolic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Metabolic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for RNA Targeting Small Molecule Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of World 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제